NeuPath Health Inc (NPTH) fair value: what the stock is really worth
As of Nov 6, 2026: fair value (intrinsic value) of NeuPath Health Inc stock C$0.58, price C$0.56, upside +3.6%, quality 58 out of 100. Rating: fairly valued. Calculated from audited financials with 13 of our 26 valuation models and 37 quality factors, updated daily.
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year. As of Nov 3, 2026.
How to read this chart
60‑month range C$0.0800 – C$0.6600 · fair‑value band C$0.4300 – C$0.7300 · the C$0.5600 price screens below the C$0.5800 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 3, 2026.
Follow NeuPath Health in your weekly email
Every Wednesday you see whether NeuPath Health is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
NeuPath Health Inc. provides chronic pain management services in Canada. It operates a network of medical clinics in Ontario and Alberta that offer assessments and rehabilitation services to patients with chronic pain, musculoskeletal/back injuries, sports-related injuries, and concussions.
Show moreShow less
The company also provides workplace health services and independent medical assessments to employers and disability insurers, as well as legal practices through a network of health care providers comprising cardiologists, dentists, dermatologists, psychiatrists, endocrinologists, gastroenterologists, general practitioners, internal medicine specialists, neurologists, neuropsychiatrists, neuropsychologists, occupational therapists, ophthalmologists, orthopedic surgeons, physiatrists, physiotherapists, psychologists, respirologists, and rheumatologists.
In addition, it operates a network of healthcare clinics and related businesses. The company is headquartered in Mississauga, Canada.
Stock analysis
NeuPath Health Inc (NPTH) currently trades at C$0.5600, while our model-based Fair Value estimate is C$0.5800, so the stock looks roughly fairly valued today (gap 3.4%).
Show more
Valuation
Bull case: the Growth DCF group reads highest at a median of C$1.09 per share, and 10 of the 13 models we run sit above the C$0.5600 price.
Bear case: the Earnings-Based group reads lowest at C$0.3300, and 3 of the 13 models stay below the price. Data coverage for this calculation is low.
Scenario range: C$0.4300 (bear) to C$0.7300 (bull), the price of C$0.5600 sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 58/100 (solid quality), in the Healthcare sector.
Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.
NeuPath Health Inc reported revenue of C$87.2M in FY2025 versus C$60.9M in FY2021, a compound +9.4%/yr. Reported net income was −C$717K in FY2025.
Key figures
Market cap C$31.4M (≈ $22.3M) Micro · P/E ratio 28.0 · P/S ratio 0.35 · EPS (TTM) C$0.0200 · Net margin 1.5% · Return on equity 7.2% · Return on assets (EBIT) 0.5% (5-year average) · Operating margin 4.4%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 27 out of 100 (low confidence).
What moves the price
The share trades about 14% below its 52-week high and 56% above its 52-week low, currently above its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −1% fair-value upside, at 4%, NPTH screens cheaper than that median.
Fair Value models
BearC$0.4300Fair Value C$0.5800BullC$0.7300
Price C$0.5600 · Upside +3.6%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Based on fiscal year 2025 figures (about 10 months old). Earnings retained since then (C$0.0172 per share) are deliberately not added.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.74/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
Revenue growth 1 year
+19.8%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+11.6%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+12.9%
Start year 2020 (pandemic)
Revenue growth 6 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+9.8%
’19
’20
’21
’22
’23
’24
’25
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−1.7% (2020) → 2.3% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed
Growth Forecast
Little optimism in the price
The price assumes less growth than the company has delivered so far.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
−3.0%
The company could shrink this much every year for the next five years and today's price would still be justified.
What forecasts expect
n/a
No analyst forecast available.
After inflation (Canada: IMF forecast 2.1% a year to 2030, 2.6% from 2016 to 2025) that is about −5.0% a year for the price.
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Medical Care Facilities · 234 stocks
Beats the industry median on 5/12 measures
A mixed picture versus its industry peers.
Valuation
Quality Score58 · Above median
Fair Value upside+3.6% · Above median
Profitability
Return on equity (12 months)7.2% · Below median
Return on assets−1.6% · Bottom 25%
Net margin (12 months)1.5% · Bottom 25%
Operating margin (12 months)4.4% · Bottom 25%
Growth and dividend
Revenue growth (quarter YoY)−1.7% · Bottom 25%
Balance sheet
Debt / equity0.27× · Above median
Valuation Multiplesvs Medical Care Facilities median · lower = cheaper
P/E (12 months)28.0× · Pricier than median
P/B1.53× · book value is mostly goodwill ⓘGoodwill and other intangible assets are larger than the equity. The book value mainly reflects prices paid for past acquisitions, so we do not rank this P/B against the peer group.
P/S (12 months)0.35× · Cheapest 25%
Price / free cash flow (fiscal year)10.0× · Cheaper than median
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "NeuPath Health Inc Fair Value". https://www.fairvalue-calculator.com/stock/NPTH
Frequently asked questions
Is NeuPath Health Inc (NPTH) overvalued or undervalued?
As of Nov 3, 2026, our model estimates a fair value of C$0.5800 versus a price of C$0.5600, about +4% upside (fairly valued).
What is the fair value of NPTH?
Our model-based fair value for NeuPath Health Inc is C$0.5800 (as of Nov 3, 2026), built from audited fundamentals. The current price: C$0.5600.
What is the quality score of NPTH?
NeuPath Health Inc has a Quality Score of 58/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for NeuPath Health Inc (NPTH)?
Our model-based price target is the fair value of C$0.5800 (as of Nov 3, 2026) from 13 valuation models. Cautious scenario C$0.4300, optimistic scenario C$0.7300. It is a calculation from audited fundamentals, not an analyst target.
What is the NeuPath Health Inc stock forecast for 2026?
Our models put fair value at C$0.5800, about +4% upside versus a price of C$0.5600 (fairly valued). Cautious scenario C$0.4300, optimistic scenario C$0.7300. The calculation is refreshed regularly with new filings.
What is the revenue of NeuPath Health Inc (NPTH)?
NeuPath Health Inc reported trailing-twelve-month revenue of about C$89.0M (latest available figure, as of Nov 3, 2026).
What growth is priced into NeuPath Health Inc (NPTH)?
For today's price to be fair in a discounted-cash-flow model, NeuPath Health Inc would have to grow free cash flow by -3.0 % per year for five years (discount rate 9.3 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew +12.9 % per year. As of Nov 3, 2026.
What discount rate (WACC) does the fair value of NPTH use?
Our models discount NeuPath Health Inc at 9.3 %: a base by market capitalisation (nano), damped by beta 0.91, country premium for Canada. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For NeuPath Health Inc that is -3.0 % per year for five years, then slowing evenly to 2 % by year ten, using the same discount rate (9.3 %) and the same formula as our fair value.
How much growth has NeuPath Health Inc (NPTH) delivered so far?
Over the past 5 years revenue at NeuPath Health Inc grew +12.9 % a year. The price currently implies free-cash-flow growth of -3.0 % per year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of NeuPath Health Inc (NPTH) growing?
The median revenue growth in the sector is +6.2 % a year. That is the yardstick for the growth priced into NeuPath Health Inc (-3.0 % per year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of NeuPath Health Inc (NPTH)?
The free-cash-flow yield on the price is 9.98 %: that much free cash flow NeuPath Health Inc produces per unit of market value. When it exceeds the discount rate of our models (9.3 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of NeuPath Health Inc (NPTH)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For NeuPath Health Inc it is C$0.5800 per share (as of Nov 3, 2026), against a price of C$0.5600. It is the blended result of 13 valuation models in 5 families (DCF Models, Earnings-Based, Multiples, Growth DCF, Economic Profit).
Is NeuPath Health Inc stock overvalued or undervalued in 2026?
As of Nov 3, 2026, NPTH trades below its calculated fair value: price C$0.5600, fair value C$0.5800, a gap of about +4% (fairly valued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of NPTH?
No. The price is what the market pays today (C$0.5600); the fair value is what the company's own numbers justify (C$0.5800). For NeuPath Health Inc the two are C$0.0200 per share apart. That gap is exactly why we show both numbers side by side.
How much is NeuPath Health Inc worth?
The market values NeuPath Health Inc at about C$31.4M (market capitalisation, as of Nov 3, 2026). Per share that is C$0.5600; our models calculate a fair value of C$0.5800 per share.
What do the bullish and bearish scenarios say about NPTH?
Our models span a range for NeuPath Health Inc: cautious scenario C$0.4300, base C$0.5800, optimistic C$0.7300 per share (as of Nov 3, 2026, price C$0.5600). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of NPTH?
NeuPath Health Inc trades at a price-to-earnings ratio of 28.0 (as of Nov 3, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of C$0.5800 is built from several models across several years. Other multiples: P/B 1.5, P/S 0.4, EV/EBITDA 9.7.
How solid is the balance sheet of NeuPath Health Inc (NPTH)?
Balance-sheet figures for NeuPath Health Inc (as of Nov 3, 2026): return on equity 7.2%, debt of 0.27 per unit of equity. They feed the Quality Score of 58/100, which measures business quality independently of the share price.
How far is NPTH from its 52-week high?
NeuPath Health Inc trades at C$0.5600, about 14% below its 52-week high of C$0.6500 and 56% above the low of C$0.3600 (as of Nov 6, 2026). Distance from the high says nothing about value: that is what the fair value of C$0.5800 is for.
Which stocks are comparable to NeuPath Health Inc?
From the same area (Healthcare) we also value HCA Healthcare, Inc, Fresenius SE, Tenet Healthcare Corporation, Dr. Sulaiman Al Habib Medical Services Group, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is NeuPath Health Inc stock attractive at the current price?
The data as of Nov 3, 2026: price C$0.5600, calculated fair value C$0.5800 (+4%), Quality Score 58/100, from 13 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of NPTH calculated?
We run NeuPath Health Inc through 13 models from 5 families: DCF Models, Earnings-Based, Multiples, Growth DCF, Economic Profit. Every model gets the same audited fundamentals; the fair value of C$0.5800 builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.3% above its aggregate fair value. NeuPath Health Inc currently trades 3% below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of NeuPath Health Inc (NPTH)?
The closing price on Nov 6, 2026 was C$0.5600. Our model-based fair value is C$0.5800, about +4% upside (fairly valued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with NeuPath Health Inc right now?
The price sits close to our fair value, market and models broadly agree here, little valuation tension. Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual.
Key figures of NeuPath Health Inc
How large is the market capitalisation of NeuPath Health Inc (NPTH)?
The market capitalisation of NeuPath Health Inc is C$31.4M (≈ $22.3M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of NeuPath Health Inc (NPTH)?
The price-to-sales ratio of NeuPath Health Inc is 0.35 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of NeuPath Health Inc (NPTH)?
Earnings per share at NeuPath Health Inc are C$0.0200 (price ÷ EPS = P/E 28.0). Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of NeuPath Health Inc (NPTH)?
The net margin of NeuPath Health Inc is 1.5% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of NeuPath Health Inc (NPTH)?
The return on equity (ROE) of NeuPath Health Inc is 7.2% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of NeuPath Health Inc (NPTH)?
On an EBIT basis the return on assets of NeuPath Health Inc is 0.5% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of NeuPath Health Inc (NPTH)?
The operating margin of NeuPath Health Inc is 4.4% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at NeuPath Health Inc (NPTH)?
Revenue at NeuPath Health Inc is growing −1.7% versus a year earlier (3y avg +11.6%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at NeuPath Health Inc (NPTH)?
Earnings per share at NeuPath Health Inc are growing +537% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net debt does NeuPath Health Inc (NPTH) carry?
The net debt of NeuPath Health Inc is C$1.7M (fiscal year 2025, ≈ 0.5 yrs of FCF). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch NeuPath Health Inc in the live analysis
One click puts NeuPath Health Inc on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.
Thin data
Nov 3, 2026